BioPharmSignal logoBioPharmSignal

Biotech News

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon, Inc. (ANNX)Annexon, Inc.Earnings

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA Tanruprubart EU Marketing Authorization Application (MAA) Under Review as the Potentially First Targeted Therapy for Guillain-Barré

Related news

NGENNervGen Pharma2026-05-18 11:15 EST

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

ANVSAnnovis Bio2026-05-15 11:30 EST

Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

BTAIBioXcel2026-05-15 11:00 EST

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

CLNNClene Inc.2026-05-14 12:00 EST

Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights

GHRSGH Research2026-05-14 11:00 EST

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

RVPHReviva Pharmaceuticals2026-05-13 20:35 EST

Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights

ABOSAcumen Pharmaceuticals2026-05-12 11:00 EST

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

NERVMinerva Neuroscience2026-08-07 11:00 EST

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

CGTXCognition Therapeutics2026-08-06 20:15 EST

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

DNLIDenali Therapeutics2026-08-06 20:01 EST

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

View all latest news

Annexon, Inc.

Classical Complement Inhibition Annexon develops therapies that inhibit the classical complement pathway, which can drive harmful inflammation and tissue damage in neurologic, ophthalmic and autoimmune diseases. Vonaprument Vonaprument is a complement inhibitor in pivotal development for geographic atrophy, an advanced form of dry...

Recent company news

ANNXAnnexon, Inc.2026-08-06 12:00 EST

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

ANNXAnnexon, Inc.2026-07-30 20:01 EST

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

ANNXAnnexon, Inc.2026-07-16 20:05 EST

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

ANNXAnnexon, Inc.2026-07-14 20:05 EST

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

ANNXAnnexon, Inc.2026-06-16 20:05 EST

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
5.60 USD
Market cap
861.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States